Company news

Island Pharmaceuticals Ltd news in 2026

Island Pharmaceuticals Ltd's news releases, calls and decks from 2026, newest first.

View company

NHP Surgeries Commence Ahead of Galidesivir Marburg Study

November 3, 2026

NHP Surgeries Commence Ahead of Galidesivir Marburg Study

November 3, 2026

Quarterly Appendix 4C and Activities Report

October 25, 2026

Letter to Shareholders, Notice of AGM & Proxy Form

October 22, 2026

USAMRIID Marburg study advances towards dosing

October 18, 2026

USAMRIID Marburg study advances towards dosing

October 18, 2026

Notification regarding unquoted securities - ILA

October 8, 2026

Galidesivir GMP manufacturing commences

October 1, 2026

Annual General Meeting - Rescheduled Date

September 29, 2026

Pivotal Marburg data secured for Galidesivir FDA pathway

August 30, 2026

Appendix 4G and Corporate Governance Statement

August 26, 2026

Annual Report to shareholders

August 26, 2026

Preliminary Final Report

August 26, 2026

Island boosts Galidesivir supply as Ebola surges

August 20, 2026

Date of AGM & Closing Date for Director Nominations

August 12, 2026

Cleansing Notice

August 11, 2026

Application for quotation of securities - ILA

August 11, 2026

Investor presentation

August 6, 2026

Quarterly Appendix 4C and Activities Report

July 29, 2026

Texas Biomed SOW accelerates pivotal FDA pathway

July 12, 2026

Investor Presentation - Ebola Clinical Program

July 7, 2026

Galidesivir approved for treatment use in in Ebola epidemic

July 6, 2026

Pause in Trading

July 2, 2026

Singapore Patent Expands Island's ISLA 101 Viral Protection

July 1, 2026

FDA Grants Orphan Designation for Galidesivir in Marburg

June 16, 2026

Investor Presentation - Asia Dengue Summit

June 15, 2026

Investor presentation

June 10, 2026

Island Secures USAMRIID Support for Galidesivir Study

June 9, 2026

Island Advances Galidesivir GMP Manufacturing for Biodefence

June 3, 2026

Island Adds Biodefence Leader as Filovirus Risks Escalate

May 20, 2026

Island Bolsters US Biodefence Readiness Ahead of Trials

May 18, 2026

Antiviral pipeline expansion through strategic collaboration

March 8, 2026

US Government collaboration for Galidesivir development

March 3, 2026

Trading Halt

March 1, 2026

Appendix 4D & Half-Year Financial Statements

February 25, 2026

Response to ASX Query Letter

February 10, 2026

$9m placement to advance US biodefence opportunity

February 3, 2026

FDA confirms Galidesivir approval pathway

February 3, 2026

Quarterly Appendix 4C and Activities Report

January 26, 2026

US Patent Granted for Galidesivir in filoviridae viruses

January 6, 2026

Ongoing engagement with the US FDA

January 4, 2026

Decks in 2026